Phase 4 Trial – Treating Men with Overactive Bladder

Dr. Steven Kaplan, a certified urologist at Mount Sinai in NY, discusses his new research in men with overactive bladder. He talks about the significance of the findings from the Phase 4, 12-week PLUS trial, what it means for urologists treating men with overactive bladder, the evolution of treatment during his career for patients with overactive bladder, the prominence of overactive bladder in men and why it remains an under-treated patient population despite 90 percent of men between 50-80 years’ experience lower urinary tract symptoms.

Dr. Steven Kaplan is Director of the Men’s Wellness Program, Mount Sinai Health System and Professor, Icahn School of Medicine at Mount Sinai. He is an internationally renowned authority and one of the primary thought leaders in the study of benign diseases, the association of metabolic factors with voiding dysfunction, and female urology, with symptoms related to both benign prostate enlargement and bladder function.

He has over 1000 publications including 600 peer reviewed and 570 peer reviewed invited articles, and 90 book chapters and non – peered reviewed articles. His landmark study, published in JAMA in 2006, changed the way medications are used in the treatment of men with symptoms related to both benign prostate enlargement and bladder dysfunction.

He has made over 340 presentations in more than 35 countries. He is the co – author of five books and is on the Editorial Board of numerous journals including Urology, Journal of Urology, and Urology Times. Dr. Kaplan is a member of more than 30 professional organizations, been awarded 5 NIH grants and has received over 13 million dollars in research funding.

Dr. Steven Kaplan serves as both member and / or Chair of numerous study sections for the NIH and more recently, he chaired the NIDDK Prostate Strategic Planning Committee and

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.